Cargando…

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols

Assiduous surveillance for genetic aberrations is necessary in patients on cytotoxic therapies to detect therapy-related myeloid neoplasms (t-MN). Current modalities include metaphase cytogenetics and FISH. Since t-MN may develop abruptly in cytogenetically normal patients, a discussion exploring ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Zeba N, Jethava, Yogesh, Post, Ginell R, Alapat, Daisy, Sawyer, Jeffrey, Waheed, Sarah, Nair, Bijay, Usmani, Saad Z, Bailey, Clyde, Petty, Nathan, Van Rhee, Frits, Barlogie, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377252/ https://www.ncbi.nlm.nih.gov/pubmed/25838910 http://dx.doi.org/10.1002/ccr3.180

Ejemplares similares

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols
por: Usmani, Saad Z, et al.
Publicado: (2012)

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing
por: Gralewski, Jonathon H., et al.
Publicado: (2018)

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)
por: Papanikolaou, X, et al.
Publicado: (2016)

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma
por: Papanikolaou, X, et al.
Publicado: (2015)

Therapy-Related Myeloid Malignancies in Myeloma
por: Papanikolaou, X., et al.
Publicado: (2011)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
por: Sawyer, Jeffrey R., et al.
Publicado: (2019)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
por: Hu, Bo, et al.
Publicado: (2013)

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma
por: Heuck, C J, et al.
Publicado: (2014)

EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
por: Ling, Wen, et al.
Publicado: (2023)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma
por: Mathur, Pankaj, et al.
Publicado: (2017)

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
por: Rasche, Leo, et al.
Publicado: (2019)

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma
por: Khan, R, et al.
Publicado: (2015)

Inhibiting MEK in MAPK pathway-activated myeloma
por: Heuck, C J, et al.
Publicado: (2016)

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
por: Usmani, Saad Z.
Publicado: (2012)

Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
por: Larsen, Kristin, et al.
Publicado: (2022)

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant
por: Rhee, June-Wha, et al.
Publicado: (2023)

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
por: Mouhieddine, Tarek H., et al.
Publicado: (2020)

Management of multiple myeloma during COVID-19 pandemic
por: Jethava, YS, et al.
Publicado: (2020)

Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
por: Danziger, Samuel A., et al.
Publicado: (2020)

C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
por: Kollu, Vidya, et al.
Publicado: (2018)

Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
por: Baker, David, et al.
Publicado: (2021)

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
por: Davies, Faith E., et al.
Publicado: (2018)

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
por: Rasche, L, et al.
Publicado: (2018)

The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry
por: Fajgenbaum, David C., et al.
Publicado: (2022)

Chromosome 1q21 abnormalities in multiple myeloma
por: Schmidt, Timothy M., et al.
Publicado: (2021)

Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
por: Tomasson, Michael H., et al.
Publicado: (2018)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu, Yi-Chang, et al.
Publicado: (2014)

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
por: Zhan, Xin, et al.
Publicado: (2017)

CD38-Directed Therapies for Management of Multiple Myeloma
por: Hashmi, Hamza, et al.
Publicado: (2021)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

ABO blood group is a determinant of von Willebrand factor protein levels in human pulmonary endothelial cells
por: Murray, Glenn P, et al.
Publicado: (2020)

Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e4vc7m4ntmq5a9opap8ibe9sop